344 related articles for article (PubMed ID: 20002080)
21. Therapeutic potential of Takeda-G-protein-receptor-5 (TGR5) agonists. Hope or hype?
Hodge RJ; Nunez DJ
Diabetes Obes Metab; 2016 May; 18(5):439-43. PubMed ID: 26818602
[TBL] [Abstract][Full Text] [Related]
22. A review of late-stage CNS drug candidates for the treatment of obesity.
Heal DJ; Gosden J; Smith SL
Int J Obes (Lond); 2013 Jan; 37(1):107-17. PubMed ID: 22410963
[TBL] [Abstract][Full Text] [Related]
23. The obesity epidemic: current and future pharmacological treatments.
Hofbauer KG; Nicholson JR; Boss O
Annu Rev Pharmacol Toxicol; 2007; 47():565-92. PubMed ID: 17002599
[TBL] [Abstract][Full Text] [Related]
24. New and emerging pharmacologic therapies for type 2 diabetes, dyslipidemia, and obesity.
Taylor JR; Dietrich E; Powell JG
Clin Ther; 2013 Jan; 35(1):A3-17. PubMed ID: 23328274
[TBL] [Abstract][Full Text] [Related]
25. Semaglutide as a promising antiobesity drug.
Christou GA; Katsiki N; Blundell J; Fruhbeck G; Kiortsis DN
Obes Rev; 2019 Jun; 20(6):805-815. PubMed ID: 30768766
[TBL] [Abstract][Full Text] [Related]
26. Companies throw their weight behind new antiobesity drugs.
Cahoon L
Nat Med; 2010 Feb; 16(2):136. PubMed ID: 20134442
[No Abstract] [Full Text] [Related]
27. CB1 receptor blockade and its impact on cardiometabolic risk factors: overview of the RIO programme with rimonabant.
Scheen AJ
J Neuroendocrinol; 2008 May; 20 Suppl 1():139-46. PubMed ID: 18426513
[TBL] [Abstract][Full Text] [Related]
28. Emerging drugs for obesity therapy.
Zanella MT; Ribeiro Filho FF
Arq Bras Endocrinol Metabol; 2009 Mar; 53(2):271-80. PubMed ID: 19466220
[TBL] [Abstract][Full Text] [Related]
29. Anti-obesity drug development.
Bays H; Dujovne C
Expert Opin Investig Drugs; 2002 Sep; 11(9):1189-204. PubMed ID: 12225242
[TBL] [Abstract][Full Text] [Related]
30. Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement.
Avenell A; Broom J; Brown TJ; Poobalan A; Aucott L; Stearns SC; Smith WC; Jung RT; Campbell MK; Grant AM
Health Technol Assess; 2004 May; 8(21):iii-iv, 1-182. PubMed ID: 15147610
[TBL] [Abstract][Full Text] [Related]
31. Past and present of antiobesity agents: focus on monoamine modulators.
Khorassani FE; Misher A; Garris S
Am J Health Syst Pharm; 2015 May; 72(9):697-706. PubMed ID: 25873617
[TBL] [Abstract][Full Text] [Related]
32. Cardiovascular effects of current and future anti-obesity drugs.
Comerma-Steffensen S; Grann M; Andersen CU; Rungby J; Simonsen U
Curr Vasc Pharmacol; 2014 May; 12(3):493-504. PubMed ID: 24846238
[TBL] [Abstract][Full Text] [Related]
33. Obesity drug therapy.
Baretić M
Minerva Endocrinol; 2013 Sep; 38(3):245-54. PubMed ID: 24126545
[TBL] [Abstract][Full Text] [Related]
34. Interrupting the natural history of diabetes mellitus: lifestyle, pharmacological and surgical strategies targeting disease progression.
Khavandi K; Brownrigg J; Hankir M; Sood H; Younis N; Worth J; Greenstein A; Soran H; Wierzbicki A; Goldsmith DJ
Curr Vasc Pharmacol; 2014 Jan; 12(1):155-67. PubMed ID: 22272898
[TBL] [Abstract][Full Text] [Related]
35. [The pharmacotherapy of obesity].
Budai KA; Mirzahosseini A; Noszál Béla ; Tóth G
Acta Pharm Hung; 2015; 85(1):3-17. PubMed ID: 26137782
[TBL] [Abstract][Full Text] [Related]
36. Management of cardiovascular risk in patients with type 2 diabetes mellitus as a component of the cardiometabolic syndrome.
Ferdinand KC
J Cardiometab Syndr; 2006; 1(2):133-40. PubMed ID: 17679832
[TBL] [Abstract][Full Text] [Related]
37. New antiobesity agents in type 2 diabetes: overview of clinical trials with sibutramine and orlistat.
Scheen AJ; Ernest P
Diabetes Metab; 2002 Dec; 28(6 Pt 1):437-45. PubMed ID: 12522323
[TBL] [Abstract][Full Text] [Related]
38. Pharmacotherapy for psychotropic drug-related weight gain.
Howland RH
J Psychosoc Nurs Ment Health Serv; 2008 Jul; 46(7):15-8. PubMed ID: 18686592
[TBL] [Abstract][Full Text] [Related]
39. Obesity pharmacotherapy - update 2023.
Haluzík M; Müllerová D; Sucharda P; Boženský J; Holéczy P; Fried M; Hainer V; Kunešová M; Málková I; Slabá Š; Šrámková P; Braunerová RT
Cas Lek Cesk; 2023; 162(1):19-31. PubMed ID: 37185039
[TBL] [Abstract][Full Text] [Related]
40. Clinical pharmacotherapy for obesity: current drugs and those in advanced development.
Halford JC
Curr Drug Targets; 2004 Oct; 5(7):637-46. PubMed ID: 15473253
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
